ZYBTNasdaqPharmaceutical Preparations

Zhengye Biotechnology Holding Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026

$1.45+0.05 (+3.57%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Zhengye Biotechnology has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Zhengye Biotechnology filed with the SEC

Aug 6, 2026, 4:10 PM ET
PRESS RELEASE - ZHENGYE BIOTECHNOLOGY HOLDING LIMITED REGAINS COMPLIANCE WITH NASDAQ BID PRICE REQUIREMENT
EX-99.1 to Form 6-K
Jul 21, 2026, 4:10 PM ET
PRESS RELEASE - ZHENGYE BIOTECHNOLOGY HOLDING LIMITED COMMENTS ON UNUSUAL TRADING ACTIVITY
EX-99.1 to Form 6-K
Jun 4, 2026, 4:05 PM ET
PRESS RELEASE TITLED "ZHENGYE BIOTECHNOLOGY HOLDING LIMITED RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY"
EX-99.1 to Form 6-K
Feb 27, 2026, 7:11 PM ET
NOTICE AND PROXY STATEMENT OF 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS, DATED FEBRUARY 27, 2026, TO BE MAILED TO THE SHAREHOLDERS OF THE COMPANY IN CONNECTION WITH THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.1 to Form 6-K
Feb 27, 2026, 7:11 PM ET
FORM OF PROXY CARD TO BE MAILED TO SHAREHOLDERS OF THE COMPANY FOR USE IN CONNECTION WITH THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.2 to Form 6-K
Dec 12, 2025, 4:10 PM ET
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
EX-99.1 to Form 6-K
Dec 12, 2025, 4:10 PM ET
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
May 23, 2025, 4:05 PM ET
PRESS RELEASE TITLED "ZHENGYE BIOTECHNOLOGY HOLDING LIMITED RECEIVES NASDAQ NOTICE RELATED TO LATE FILING OF FORM 20-F"
EX-99.1 to Form 6-K
Jan 14, 2025, 4:10 PM ET
PRESS RELEASE DATED JANUARY 14, 2025, ANNOUNCING THE EXERCISE OF THE OVER-ALLOTMENT OPTION
EX-99.1 to Form 6-K
Jan 8, 2025, 4:10 PM ET
PRESS RELEASE DATED JANUARY 6, 2025, ANNOUNCING THE PRICING OF THE IPO
EX-99.1 to Form 6-K
Jan 8, 2025, 4:10 PM ET
PRESS RELEASE DATED JANUARY 8, 2025, ANNOUNCING THE CLOSING OF THE IPO
EX-99.2 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Zhengye Biotechnology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ZYBT.

Revenue growth-37.6% · median 23.6%

Gross margin20.5% · median 73.9%

Operating margin-60.6% · median -35.1%

Net margin-60.0% · median -23.6%

Company	Revenue	Growth
PAHC	$1.52B	+17.1%
GYRE	$119.38M	+13.5%
ZYBT	CN¥116.36M	-37.6%
ZOMDF	$36.88M	+30.1%
JAGX	$27.82M	+135.5%
BGM	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Employees: 51
Auditor: WWC, P.C.
SEC CIK: 1975641

Advertisement
300 × 250